<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01724697</url>
  </required_header>
  <id_info>
    <org_study_id>20120912-1</org_study_id>
    <nct_id>NCT01724697</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Human Bone Marrow Stem Cells for Treatment of HBV-related Liver Cirrhosis</brief_title>
  <official_title>Safety and Efficacy of Human Autologous Bone Marrow Stem Cells for Treatment of HBV-related Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Second Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Hepatobiliary Surgery Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fourth Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HBV related Liver disease is a common medical problem in China. An estimated 7.18% of the
      Chinese (about 93 million) is infected with hepatitis B, and most of the HBV- related
      hepatitis can developed into liver cirrhosis.

      Liver transplantation is the only available life saving treatment for patients with end stage
      liver disease. However, lack of donors, surgical complications, rejection, and high cost are
      serious problems.

      stem cells(SCs) possess plasticity and have the potential to differentiate into hepatocyte;
      Thus, SCs hold great hope for therapeutic applications. Adult bone marrow is the most common
      source of SCs for clinical applications.Previous study showed that bone marrow derived stem
      cells (BMSCs) replace hepatocytes in injured liver, and effectively rescue experimental liver
      failure and contribute to liver regeneration. In this study, the patients with HBV-related
      liver cirrhosis will undergo administration of human autologous BMSCs via hepatic artery to
      evaluate the safty and efficacy of human autologous BMSCs treatment for these patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>one year survival rate</measure>
    <time_frame>one year after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>MELD score</measure>
    <time_frame>1week, 4weeks, 3months, 6months, 9 months and 1year after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AFP</measure>
    <time_frame>1week, 4weeks, 3months, 6months, 9 months and 1year after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function</measure>
    <time_frame>1week, 4weeks, 3months, 6months, 9 months and 1year after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>child score</measure>
    <time_frame>1week, 4weeks, 3months, 6months, 9 months and 1year after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>End Stage Liver Disease</condition>
  <arm_group>
    <arm_group_label>conventional treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>conventional treatment &amp; antivrial treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMSC transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>conventional treatment &amp; antiviral treatment &amp; autologous bone marrow stem cell transplantation via hepatic artery</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>BMSC transplantation</intervention_name>
    <description>Patients randomized to the intervention arm will be collected for bone marrow stem cells and then infused with these cells via hepatic artery.</description>
    <arm_group_label>BMSC transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>conventional treatment &amp; antivrial treatment</intervention_name>
    <description>Participants will recieve conventional treatment and antivrial treatment.</description>
    <arm_group_label>conventional treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18-65 years

          2. HBV-related liver cirrhosis

          3. Child-Pugh score 9-15

          4. Written consent

        Exclusion Criteria:

          1. Hepatocellular carcinoma or other malignancies

          2. Severe problems in other vital organs(e.g.theheart,renal or lungs)

          3. Pregnant or lactating women

          4. Severe bacteria infection

          5. Anticipated with difficulty of follow-up observation

          6. Other candidates who are judged to be not applicable to this study by doctors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daiming Fan</last_name>
    <role>Study Chair</role>
    <affiliation>Fourth Military Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xijing Hospital of Digestive Disease</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Han</last_name>
      <phone>86-29-84771539</phone>
      <email>hanying@fmmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yongquan Shi</last_name>
      <phone>86-29-84771515</phone>
      <email>shiyquan@fmmu.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2012</study_first_submitted>
  <study_first_submitted_qc>November 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 12, 2012</study_first_posted>
  <last_update_submitted>November 7, 2012</last_update_submitted>
  <last_update_submitted_qc>November 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fourth Military Medical University</investigator_affiliation>
    <investigator_full_name>Han Ying</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>liver cirrhosis</keyword>
  <keyword>end stage liver disease</keyword>
  <keyword>HBV</keyword>
  <keyword>autologous</keyword>
  <keyword>stem cell</keyword>
  <keyword>bone morrow</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

